Shares of CytomX Therapeutics (NASDAQ:CTMX) tumbled 5.20% in pre-market trading on Thursday after analysts significantly downgraded their forecasts for the company. The dramatic revision has cast a shadow over the biotech firm's future prospects, leading to a sell-off among investors.

According to the latest analyst consensus, CytomX Therapeutics is now expected to generate revenues of just US$31 million in 2026, a substantial reduction from the previous estimate of US$50 million. This revision implies a painful 73% decline in sales compared to the last year of performance. More alarmingly, the company is now projected to slip into loss-making territory, with analysts forecasting losses of US$0.40 per share in 2026, compared to the earlier expectation of US$0.27 per share loss.

The downgrade paints a grim picture for CytomX Therapeutics' growth trajectory. While the broader industry is anticipated to see revenue growth of 22% annually for the foreseeable future, CytomX is expected to experience a significant contraction. Analysts project an annualized revenue decline of 65% by the end of 2026 for the company, a stark contrast to its 22% annual growth over the past five years. This pessimistic outlook has clearly spooked investors, resulting in the pre-market plunge as traders reassess their positions in light of the company's challenging future.